Clearpoint Neuro is trading 6.4% up at $14.25 after recovering from the August 3 earnings-driven decline alongside broader healthcare strength.

  • The healthcare sector was rising 1.3% in recent trading.
  • No new company-specific announcement was identified for August 7, 2026.
  • Second-quarter revenue was $10.9 million; 2026 guidance was reduced to $48 million–$52 million.